F2 and inflammatory bowel disease: Factor V Leiden deficiency and prothrombin G20210A mutation delineated 10% of the individuals with an approximately 2.5-fold increased likelihood of developing TED compared with non-high-risk controls, which is attributed to risk factors, including disease flare, extended disease location, and steroid use; a higher genetic risk was associated with TED events, suggesting that these IBD patients might warrant more aggressive prophylaxis against TED [9].